Showing posts with label KDA. Show all posts
Showing posts with label KDA. Show all posts

Monday, January 14, 2019

Using Exercise and Other Physical Therapy Interventions to Optimize Functional Mobility

Below is a link to a PDF that was used for a presentation at the KDA annual conference. Anyone who follows my blog knows that I highly recommend developing a frequent and sustainable "smart" exercise program for those of us living with Kennedy's Disease (SBMA). The presentation expounds upon the benefits of a regular exercise program as well as provides warnings and tips.

As always, I recommend three things:
1. Consult with your doctor and a physical therapist before beginning any exercise program.
2. A PT familiar with KD or ALS is essential in the design of a sustainable program.
3. Don't overdo. Listen to your body.

Using Exercise and Other Physical Therapy Interventions to Optimize Functional Mobility

Joseph Shrader, PT, CPed

Click on this link to see some other presentations that given at the annual conference.

Thursday, March 9, 2017

Silicon Valley man takes on Kennedy’s Disease

I just finished this article written by Jacqueline Lee in The Mercury News. Ralph is the gentleman that made the Kennedy's Disease Awareness video on Rare Disease Day. Ralph is definitely doing everything he can to raise awareness for this progressive neuromuscular disease. Thank Ralph

Silicon Valley man takes on Kennedy’s Disease


"These days, Ralph Briones, 42, has trouble walking up stairs, jogging, swallowing food or lifting heavy groceries.

Still, Briones is using what energy he has to raise awareness about Kennedy’s Disease. He was diagnosed in October with the relatively unknown neurological condition, which affects about 1 in 40,000 adult men.

On Rare Disease Day, which was Feb. 28 this year, Briones launched an online campaign to raise at least $10,000 to further research on the genetic disease that still baffles scientists, doctors and patients: There is no cure or treatment.

All proceeds go to the Kennedy’s Disease Association, which awards annual grants for research.

Just looking at Briones, who continues to work at Stanford University, does not offer many clues of his suffering.

“If you’ve known me a while though, you’d say, ‘You sound kind of funny, you’re walking kind of funny, your smile is crooked,’” Briones said.

That’s because the adult onset disease causes muscle weakness and deterioration, especially in the arms, legs, face and throat. The disease progresses at a different pace in each patient.

Eventually, Briones might not be able to talk or walk. But he’s focusing on the positive.

“When I got diagnosed with Kennedy’s Disease, the first thing I thought was, ‘How long do I have to live?” said Briones, a Santa Clara father of two. “From what I’ve seen, it’s not something that will shorten my life or that I’ll die from quickly.”

A video on Briones’ fundraising site, www.gofundme.com/kennedysdiseaseresearch, features men from around the world — Australia to Taiwan to Michigan — with different symptoms at varying severity.

Kennedy’s Disease patients often are misdiagnosed with ALS, which has similar symptoms. The disease is difficult to diagnose because it’s not on doctors’ radar and requires genetic testing for confirmation, Briones said.

When Briones first experienced symptoms in his late 30s, he thought he was just feeling the effects of aging, so he started to work out daily. Briones, who actively played tennis, snowboarded and danced until his mid-30s, noticed though that he wasn’t building muscle. His muscle cramps and spasms worsened, and workouts would leave him feeling unusually fatigued and sore.

After many doctor consultations, blood tests and an MRI that didn’t turn up anything, Briones and his wife discovered in online research that his symptoms matched Kennedy’s Disease. They asked for a DNA test and, sure enough, it was a match, Briones said. Briones later learned his mother was a carrier.

Because there is no cure or treatment, Briones has had to figure out how to live with the disease. His community through the Kennedy’s Disease Association is a big help. ..."

To reaad the entire article, follow this link: The Mercury News

Sunday, January 29, 2017

A New Walking Assist Device

I am always looking for the latest and greatest device to make life more manageable. The other day I received an email from a KDA board member that caught my interest.

The website has several videos showing the device being worn by different people. Keeogo appears to be an 'assisting' device. The ability to maintain your balance is important.

Today's technological capabilities continue to move closer to a true mobility aid for those of us living with a progressive neuromuscular disorder. And, eventually, I hope healthcare providers will recognize the importance of these devices for maintaining quality of life.


Hello all,
I was at a abilities show today and came across  a device that
I am very excited about. It was developed by a Canadian firm 
and seems to be similar to the Honda device that is in 
development. It is currently on the market in Canada selling 
for about $45,000. Hopefully this price will come down 
substantially as these devices are mass produced. I have 
provided a link below for you to view a video of the device. 



Monday, November 28, 2016

Did you miss the KDA Conference and Educational Symposium?



I did too. I understand there was 104 attendees.

Six of the clinical presentations are posted on the KDA website. I know, it isn't the same as being there and having the presenter explain each slide and answer questions, but it is better than nothing.

Personally, I found the one on Pain and Kennedy's Disease to be enlightening. And, Dr, Jordan's presentation on what causes all these crazy things to happen is challenging a lot of what we were told. I am hoping it leads to breakthroughs.

You might also want to check out Paul Lazenby's Facebook comment on the SFN Conference that Paul attended after the KDA Conference.


Saturday, November 5, 2016

2016 Research Grants Awarded

The Kennedy’s Disease Association announced the recipients of the 2016 research Grants. The following projects have been awarded $50,000 each. Congratulations!

Dr Bilal Malik, Professor Greensmith’s Lab, UCL, Institute of Neurology, UK

Targeting pathways of disease in Spinal Bulbar and Muscular Atrophy (SBMA)

Spinal and Bulbar Muscular Atrophy (SBMA), also known as Kennedy’s disease (KD), is adult-onset slowly progressing rare inherited neuromuscular disorder that primarily affects males. As yet there are no effective treatments that can cure the disease or delay its progression. The disease is primarily characterized by muscle weakness and wasting, and degeneration of motor neuron cells within the spinal cord and brain.

Our aim is to establish why motor neurons and muscles degenerate in SBMA by investigating the genes and pathways that underlie disease. The identification of changes that occur early in disease may identify the mechanisms responsible for disease and help establish novel therapeutic targets. This proposal offers the unique opportunity to undertake a comparative study of two platforms that model SBMA, each with its own merits: i) a well-characterized mouse model in which muscle and motor neurons can be examined at various stages of disease, and ii) human cell models, including stem-cell derived motor neurons and patient muscle cells acquired from biopsies. By comparing and contrasting the changes in gene expression in these models of the specific cells affected in SBMA we hope to identify the key changes in gene expression that take place early in disease, identifying a common signature in the pathways of pathology. The results of this study will not only help define novel therapeutic targets with a greater level of confidence by analyzing several complimentary models of SBMA, but also allow us to test treatment strategies in a human cell model of the disease.
 ________________________

Dr. Janghoo Lim, Yale University School of Medicine

The role of VCP in the pathogenesis of Kennedy's disease

Spinal and Bulbar Muscular Atrophy (SBMA; Kennedy’s Disease) is a neuromuscular disease that affects motor neurons and skeletal muscles. The symptoms of SBMA include progressive weakness of the limbs and facial muscles, as well as difficulty with speaking and swallowing.  SBMA is an X-linked disease that primarily affects men, and is caused by a polyglutamine expansion in the gene Androgen Receptor (AR). The polyglutamine expansion in AR makes the protein toxic, and can lead to the formation of protein aggregates inside of cells as well as cell death. SBMA is one of nine different polyglutamine expansion disorders that are linked to neurodegeneration. How polyglutamine expanded AR causes SBMA is still being studied, and there are no effective therapeutics available. In order to better understand the mechanisms that cause SBMA and translate these results into the development of effective therapeutics, my proposal aims to assess how the protein Valosin-Containing Protein (VCP) is involved in SBMA.  VCP plays a role in breaking down mutant or damaged proteins, and has been studied in other neurodegenerative disorders. Based on our preliminary data, we hypothesize that VCP can regulate the expression and/or the activity of polyglutamine expanded AR. Our proposal will examine how VCP affects the development of protein aggregates and cell death in SBMA. We will use cell culture models and fruit flies, both of which are commonly used to study SBMA. This research will help develop a more thorough understanding of what causes SBMA, and provide important information when developing new therapeutics for this devastating disease.
_________________________

Manuela Basso, Ph.D., Assistant Professor, Laboratory of Transcriptional Neurobiology, Centre for Integrative Biology, University of Trento, Italy

Insights into the molecular pathology of SBMA: Targeting PRMT6 to attenuate the disease


In collaboration with the Laboratory of Dr. Pennuto, we have recently discovered that a protein, called PRMT6, exacerbates the toxicity induced by mutant androgen receptor, while its inhibition rescues it in cells and flies. Our strategy is to develop a therapy that preserves AR physiological functions while abolishing the toxicity acquired upon polyglutamine expansion. Thus, we propose to silence PRMT6 both via selective pharmacological inhibitors and via gene-silencing to choose the best system to move our studies in pre-clinical models.

Wednesday, September 7, 2016

I still need to remind myself …

I like to consider myself a fairly optimistic and upbeat person. However, occasionally, I need to remind myself that things could be a whole lot worse.

  • Kennedy’s Disease’s progression isn’t fun, but it is slow. There is plenty of time to adjust your lifestyle and work on acceptance.
  • Researchers move closer to finding a treatment every year. When I was first diagnosed, there was only a glimmer of hope. Now, researchers are trampling on the doorstep.
  • Current mobility aids have come a long way in helping to ease the transition process. 
  • A support system is in place. In the last fifteen years, the Kennedy’s Disease Association, KDA, has grown from its infancy to an organization capable of supporting those living with this condition throughout the world.


I keep these two posters on my desktop. They say it all.



Sunday, December 20, 2015

The Annual Kennedy's Disease Conference was held in Chicago this year. The post-conference newsletter is now available for reading (PDF) online. There are several excellent articles on current research as well as plenty of conference news. I have copied a couple of the articles that might be of interest.

____________________________
Research News at the 2015 KDA Conference
Ed Meyertholen, Ph.D.
KDA Board Member, and Scientific Review Board Member
Assistant Dean, Georgetown College, Georgetown University, Washington, DC


The annual conference of the Kennedy’s Disease Association was held this past October in Chicago. We are lucky in that we have a group of researchers that not only are dedicated to finding a treatment for KD but also able to find time to present their most recent research at the meeting. In addition, our meetings also allow for the interaction between the researchers and the conference attendees. This is by far the most rewarding part of the conference for me personally.
As is typical, researchers who came to the meeting were from most of the labs in the USA and Canada that make major contributions to KD research as well as some from across the pond. The research described at the meeting is generally unpublished work and as a result, is not usually ready for broad distribution. For me, however, one of the more interesting and encouraging developments this year actually was not a part of our conference and did not even deal with KD but its close cousin, Huntington’s Disease (HD). A new clinical trial using something called anti-sense oligonucleotides (ASO) had started this summer. Without going into excruciating details, ASO’s prevent the production of the protein that causes HD and as a result, the symptoms of HD in mice were reduced with the injection of this ASO. The success of these experiments in mice led to the formation of the clinical trial to use ASO’s in humans. Experiments using ASO’s against the androgen receptor (the protein affected in KD) in mice have also shown to be effective in relieving symptoms of KD. Thus, if this treatment works in HD patients, it should work in KD as well.
The KDA Conference is also the site of the notification and presentation of the research grants funded by the KDA. This year, thanks to your donations and fund raisers two grants were awarded at the conference, one to Dr. Miltiadis Paliouras (principle investigator) and Dr. Lenore Beitel (co-applicant) who are Assistant Professors at McGill University; and the other to Dr Constanza Cortes, a post-doctoral researcher in Al La Spada’s lab at UC-San Diego. The competition for the grants was extremely fierce this year as a record number of proposals were submitted – all of them of excellent quality.
____________________________


Exercise Research 
Joseph A Shrader, PT, C.Ped 
Senior Clinical and Research Physical Therapist, Clinical Research Center, NIH

Recent evidence suggests that functional exercises aimed at improving functional tasks such as
sitting up, rolling over, sit-to-stand, and stepping up an 8-inch step were well tolerated by persons with spinal and bulbar muscular atrophy when supervised by rehabilitation and/or nursing professionals. Overall, strength, balance, function, and quality of life did not differ between those who received the exercise versus stretching (control group), however, those with relatively low baseline function improved their functional profile and those with relatively high baseline function improved their general activity level, compared with the control group. More research is needed to help optimize exercise intensity, mode, frequency and duration for individuals with KD. General recommendations for people with KD include attempting to incorporate daily physical activity into your lifestyle, along with good nutrition and sleep habits. If you experience falls, fear of falling, leg weakness, requirement of assistance or assistive devices for standing and walking, it is recommended that you first be examined by your primary doctor, neurologist, or physiatrist to discuss contraindications and exercise goals. It is also recommended that exercises be initially prescribed and monitored for appropriate post-exercise recovery by a physical therapist, until a safe and sustainable self-directed program can be assured.

NIH does not endorse or recommend any commercial products, processes, or services. The views and opinions of NIH authors do not necessarily state or reflect those of the U.S. Government, and they may not be used for advertising or product endorsement purposes.

Tuesday, September 29, 2015

NORD Press Release on approval of Ensuring Access to Clinical Trials

The Kennedy's Disease Association (KDA), as well as hundreds of other organizations, supported the passage of S. 139. Many of us living with Kennedy's Disease, as well as other Rare Disorders, also contacted their Senators and Representatives asking for their support.


NORD Issues Statement Applauding the Approval of Ensuring Access to Clinical Trials Act
Washington, D.C.—September 29, 2015—The following statement was issued by Peter L. Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), on yesterday’s approval of the Ensuring Access to Clinical Trials Act (S. 139) in the United States House of Representatives.
The House of Representatives echoed the U.S. Senate and showed its commitment to 1 in 10 Americans and their families by passing the Ensuring Access to Clinical Trials Act (S.139).  By passing S. 139, the House voted to remove income-related barriers to participation in clinical trials and toward developing much-needed treatments for the 7,000 known rare diseases, only a few hundred of which currently have FDA-approved treatments.
Today, 30 million people and their families have added hope that their tremendous unmet medical needs are one step closer to being addressed. Studying one rare disease can often lead to understanding of other rare diseases, as well as understanding of more common diseases.
As the Ensuring Access to Clinical Trials Act moves to the President’s desk, we close in on eliminating the challenges of rare diseases and to stopping them from altering and ending the lives of too many Americans much too soon.  NORD is proud to have supported this bill and to have advocated for its passage with the Cystic Fibrosis Foundation, Muscular Dystrophy Association, and many others in the rare disease community.
Peter L. Saltonstall
President and CEO, National Organization for Rare Disorders (NORD)

Read more about the Ensuring Access to Clinical Trials Act here.
###
About the National Organization for Rare Disorders (NORD)®
Established in 1983, the National Organization for Rare Disorders (NORD)® is the primary nonprofit organization representing all patients and families affected by rare diseases in the U.S.  NORD is committed to the identification, treatment and cure of all 7,000 rare diseases that affect 30 million Americans, or one in every 10 people.  NORD provides programs of advocacy, education, research and patient and family services to improve the lives of all people living with rare diseases. NORD represents more than 230 disease-specific member organizations and collaborates with many other organizations in specific causes of importance to the rare disease patient community. Join NORD at www.rarediseases.org and on Twitter at @RareDiseases.
 ________________

The MDA also made an announcement today regarding the passage of this act. You can read the announcement at this link:  http://cqrcengage.com/mda/advocacy/issues/eact

Sunday, June 14, 2015

Personal Stories tell the real story



Below is another story of a family living with Kennedy's Disease and their efforts to help find a cure for this condition. The non-profit they formed is in Great Britain. 

Starting up a non-profit is never easy. Susanne and Terry Waite started the Kennedy's Disease Association (KDA) fifteen years ago. They sacrificed a lot to make it happen and even more to grow the KDA into what it is today. 

I applaud the efforts of Ms. Hopps and her team and wish them the best as they move forward with KD-UK. Their website is: http://kennedysdiseaseuk.com/  




“Monday 8 June 2015
A NEW national charity aimed at tackling a rare neuromuscular disorder has been launched by a Dorset woman.

Kate Hopps (right) with her sister, Louse
When Kate Hopps, 43 of Martinstown, found out her husband of 21 years Frank had Kennedy’s Disease, her world was turned upside down. 

Kennedy's Disease (KD) is described as an inherited motor neuron disease that affects men. There is no cure for the disease and no current treatment. 

Kate said: “It's very scary when you're told that your husband has this disease because so few people know about it.” 

Saturday, June 13, 2015

Nice one-page synopsis

I came across this one-page PDF on Kennedy's Disease on the ALS Society of Canada website.

https://www.als.ca/sites/default/files/files/Fact%20Sheets/Kennedy%27s%20Disease.pdf

This is a well thought out document providing a good deal of information on Kennedy's Disease, aka Spinal Bulbar Muscular Atrophy. It could be printed and taken to your doctor, or the link could be shared with anyone interested.

I am hoping the KDA will development something like this. Check it out when you have a chance and let me know what you think.

Sunday, February 12, 2012

Pay-it-forward

payitforward

Last week I sent out the Kennedy’s Disease Association’s 2011 annual report. As in past years, it always amazes me how much can be accomplished by an all-volunteer non-profit in one year. At the same time I consider how much more could be done with more volunteers.

I have never been a proponent of hiring an office staff or paying a commission to telephone solicitors. I hate those ‘canned’ phone calls and all the mailings that include small giveaways in hopes of enticing you to give.

Yet, it would be nice to have more ‘feet on the ground’ that are focused on the KDA’s work. We do so much good with so few resources. It still amazes me that 90¢ of every dollar spent by the KDA goes to Kennedy’s Disease research (80¢) and Kennedy’s Disease education (10¢).

When I review the financial reports of some of the larger non-profits, I cannot believe how much is spent on salaries, overhead and fund raising. On the other hand, most of these larger non-profits seem to be quite effective in raising needed funds.

KDA Logo I don’t know how much longer I will serve as president of the KDA, but I do know that these last seven years have been some of the most rewarding years of my life. I have made many friends and shared many stories. I have helped some people and have been helped by so many more. In some ways it reminds me of the concept “pay-it-forward.”

Today’s article is a long-winded way of saying “THANK YOU” to all of your who have donated your time and/or money to make the Kennedy’s Disease Association so effective. Without you there would be no KDA.

Tuesday, December 20, 2011

I am becoming a little bored

As I mentioned in my dutasteride update, I upped my exercise routine to 120 minutes every other day this last month. Guess what? I was becoming bored.

 Exercise 4 I found myself not enjoying the exercise program as much as I have in the past. I felt it was too long ... versus too much. I also didn’t feel I was gaining any real benefit from the longer routine.

Yesterday I decided to back off a little (less reps) to determine if that would help. I cut back all the upper body exercises by 15%. The exercise program was more pleasant and I did not feel like I was just going through the motions near the end. It took 95 minutes and afterward I felt like I enjoyed the exercise routine again.

It was also nice to have the extra 25 minutes in the morning. So, I’ll try the shorter routine for this next month and not worry about it. If I see the need to step it up, I will.

*    *    *

Change to KDA website

On another subject, have you visited the KDA website recently? I added a “What’s New” section. Whenever you visit the site, this page will summarize any recent changes by Topic, date and subject.

Whats New

The “What’s New” link can be found under the banner and also on the left side-menu.  Check it out when you have a chance.
 

HAPPY HOLIDAYS

Sunday, November 27, 2011

Kennedy’s Disease and Recent Research

Androgen Receptor with KD The 2011 Kennedy’s Disease annual conference and educational symposium was held this month.  Over twenty researchers were involved in the conference and many gave updates on their current research.

Jack Durning recorded some of the presentations and released them to YouTube this week. 

Presentations Available

Ed Meyertholen, the KDA’s guru in explaining Kennedy’s Disease, was one of the presenters.  From the attendees after-conference survey, most everyone rated Ed’s discussion as one of the most interesting.  Ed’s presentation is five 15 minute videos and one six minute video.  Ed explains Kennedy’s Disease, DNA, bindings, folding, the ‘wood-chipper’, cytoplasm, clinical trials, placebos and much more.

Ed, unfortunately, did not use a mike.  There were many times he was not facing the recorder’s mike so he is more difficult to hear.

Part 1:  http://www.youtube.com/watch?v=02Jooy9LD_4
Part 2:  http://www.youtube.com/watch?v=DS1m82l164Q
Part 3:  http://www.youtube.com/watch?v=Vf4BQT2fEec
Part 4:  http://www.youtube.com/watch?v=AK1Ag-bTSsw
Part 5:  http://www.youtube.com/watch?v=7-UPuQTJCfo
Part 6:  http://www.youtube.com/watch?v=bkDQVumf7-E

Below is a link to Dr. Lenore Bietel’s presentation.  Lenore is aresearcher 6 Kennedy’s Disease researcher located in Canada.  She gives a thirteen minute presentation on her lab’s research project including discussing whether the PolyQ AR clogs up Proteosomes as well as a study of the androgen receptor and the protein interaction connection.

Link:  http://www.youtube.com/watch?v=pNg88tasvqI

And, the following link is for Dr. Masahisa Katsuno’s presentation of his research including an explanation of neuro-degeneration and the leuprorelin clinical trial.  This recording starts a few minutes late into the presentation.

Link:  http://www.youtube.com/watch?v=u6gPGUgI-KY

QUESTIONS?  If you have any questions, please let me know and I will try to have them answered.

Friday, October 14, 2011

KDA Awards $65,000 in Research Grants

 KDA Logo
Thanks to the generosity of its supporters, the Board of Directors of the Kennedy’s Disease Association announced today that they awarded three research grants.  The three recipients and a brief explanation of their research are shown below.
_________________________________

1.  Masahisa Katsuno, M.D. – Ph.D.,  Department of Neurology, Nagoya University Graduate School of Medicine


Amount Awarded:  $25,000


Proposal:  Elucidation of neuronal death signaling pathways and development of disease-modifying therapies for Kennedy’s disease
Research
Brief Explanation: Their lab has evidence that the synthesis of two proteins are affected by the defective androgen receptor in KD. They wish to determine if neuronal cell death is caused by the alteration in the levels of these proteins and if cell death can be prevented by the addition of drugs that target the activity of these proteins.


2.  Elise Kikis, Ph. D., Northwestern University

Amount Awarded:  $20,000 


Proposal:  Modeling SBMA: from understanding proteotoxicity to identifying therapeutics


Brief Explanation: They believe that the specific cell death is due to the
researcher 6 accumulation of misfolded proteins (the androgen receptor) and the inability of cells to handle this accumulation. They propose to use a new model organism (a little worm called C. elegans – a very common and important model system in biology) to examine how different cell types handle the misfolded proteins and genetically look for other proteins that may help the cell get rid of the messed up proteins.


3.  Sara Parodi, Ph.D., Department of Neuroscience and Brain Technologies, Genoa, Italy

Amount Awarded:  $20,000 


Proposal:  Identification of PKA signaling as a new therapeutic approach for SBMA


Brief Explanation:  There is evidence that the cell death may involve changes to the androgen receptor (specifically changes in which phosphate is added to the protein, a process called phosphorylation). They hope to determine whether this cell death can be stopped due to the activation of another protein, known as PKA.